The emergence of multidrug-resistant strains of Mycobacterium tuberculosis underscores the need of continuous developments on new and efficient methods to determine the susceptibility of isolates of M. tuberculosis in the search for novel antimicrobial agents. Natural products constitute an important source of new drugs, but design and implementation of antimycobacterial susceptibility testing methods are necessary for evaluate the different extracts and compounds. A number of biological assay methodologies are in current use, ranging from the classical disk diffusion and broth dilution assay format, to radiorespirometric (BACTEC), dye-based, and fluorescent/luminescence reporter assays. This review presents an analysis on the in vitro susceptibility testing methods developed for determinate antitubercular activity in natural products and related compounds (semi-synthetic natural products and natural productsderived compounds) and the criteria to select the adequate method for determination of biological activity of new natural products.
INTRODUCTION
Human tuberculosis (TB) is a contagious-infectious disease mainly caused by M. tuberculosis, which is an aerobic pathogenic bacterium that establishes its infection usually in the lungs (25) . About one third of the world's population is currently infected with M. tuberculosis; 10% of those infected will develop clinical disease, particularly those who also have the human immunodeficiency virus (HIV) infection. The infectious killer disease, -TB, -is the leading cause of death worldwide from a single human pathogen (65) . The World Health Organization (WHO) estimates that active cases of tuberculosis afflict seven to eight million people annually, and lead up to three million deaths per year (12) .
Although there are different regimens for treating tuberculosis in the practice, they all are far from ideal. Because these regimens are extremely difficult to follow it, WHO recommends a program of directly observed treatment (DOTS) (47) . Only 21% of the world's TB patients were treated under DOTS in 1998. There are five reasons usually given for needing new tuberculosis drugs: (1) to improve current treatment by shortening the total duration of treatment and/or by providing for more widely spaced intermittent treatment, (2) to improve the treatment of multi-drug-resistant (MDR-TB) Various reasons have been put forward to explain the success of natural products in drug discovery: their high chemical diversity, the effects of evolutionary pressure to create biologically active molecules, the structural similarity of protein targets across many species, and so on (33) .
Given the past contributions of natural products to drug discovery and given the fall in the number of new medicines introduced each year (FDA drug approvals down from ~40 in 1996 to ~20 in 2006), it seems surprising that natural productbased drug discovery has fallen so far out of fashion with the pharmaceutical industry. Some of the reasons behind that shift are caused by the difficulties in accessing natural products in ways that are compatible with high throughput screening (33).
For the above reasons, it is important to develop new strategies for evaluation and discovery of antimycobacterial drugs, the aim of the present review is to provide and discuss different in vitro methods for discover antitubercular agents in natural products research, and offer a guide for researchers to select an adequate method for determinate biological activity.
Activity-Bioassay guided
Most collections of natural products start as extracts of fresh or dried material prepared by using various solvents. The 
Anti-TB in vitro bioassays
Agar diffusion: The paper disk diffusion bioassay as well as agar diffusion assays were first developed for bacteria (21, 32 
Toxicology assays
Toxicity is a leading cause of attrition at all stages of the drug development process (5, 39) . In vitro toxicology assays can be divided on the basis of timing and purpose of the application into prospective assays and retrospective assays (5, 39) . Prospective in vitro toxicology assays are those assays that are conducted before the first in vivo toxicology studies, and attempt to predict toxicities that are development-limiting.
These include assays for general or cell-type-specific cytotoxicity, genotoxicity, hERG (human ether-a-go-gorelated, also known as KCNH2) channel block, drug-drug interactions and metabolite mediated toxicity. These cytotoxicity assays are often among the earliest toxicity assays to be conducted. In vitro cytotoxicity assays can be valuable for interpreting the results of in vitro safety and efficacy assays. Results for many of the in vitro assays detailed below may be confounded by cytotoxicity; indeed, the Ames assay and micronucleus assay include an assessment of genotoxicity that is critical for the interpretation of the assay results (5, 39).
Dormant tubercle bacilli assays
An important problem in tuberculosis control is the persistence of M. tuberculosis despite chemotherapy (24) . A stage of latency in tubercle bacilli has been found as principle cause for most of the problems associated with the disease (64) . There is still no specific drug available in the market, which could effectively kill this latent bacillus (38) . The obstacle in the development of novel drugs is caused to the lack of a screening system, which can determine inhibitors of latent bacilli of tuberculosis (38 (38) .
Macrophages assays
In vitro models of macrophage infection by 
Criteria for activity
In anti-infective in vitro models, the activity of extracts or 
